Literature DB >> 6406058

Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers.

K Hirai, K Ueda, O Hayaishi.   

Abstract

The activities of three principal enzymes engaged in the biosynthesis and degradation of poly(adenosine diphosphate-ribose) [poly(ADP-ribose)] were examined in cell nuclei isolated from adenomatous polyps (tubular adenomas of familial polyposis coli, villous adenoma, and tubulovillous adenoma), cancers, and normal mucosa of human colon. The activities of poly(ADP-ribose) synthetase in adenomatous polyps [161 +/- 46 (S.E.) pmol/min/mg DNA] and cancers (114 +/- 32 pmol/min/mg DNA) were, on an average, about 3 and 2 times, respectively, higher than those in normal mucosa (52 +/- 24 pmol/min/mg DNA); the difference was statistically significant (p less than 0.001). The activity of poly(ADP-ribose) glycohydrolase was also significantly high in adenomatous polyps (13.0 +/- 3.4 nmol/min/mg DNA), but not in cancers (10.1 +/- 2.5 nmol/min/mg DNA), compared with normal mucosa (5.2 +/- 1.4 nmol/min/mg DNA) (p less than 0.001). The activity of ADP-ribosyl protein lyase, in contrast, was lower in adenomatous polyps (152 +/- 40 pmol/min/mg DNA) than in normal mucosa (345 +/- 111 pmol/min/mg DNA) and cancers (288 +/- 80 pmol/min/mg DNA) (p less than 0.001). Analyses of reaction products with snake venom phosphodiesterase digestion revealed that poly(ADP-ribose) synthesized in nuclei of normal mucosa, adenomatous polyps, and cancers had the average chain lengths of 2.9, 1.7, and 9.7 ADP-ribose units, respectively. Based upon these values and total amounts of ADP-ribose incorporated, the amount of poly(ADP-ribose) synthesized per mg DNA in 30 min was calculated as 308, 1510, and 106 pmol in the above three types of colon tissues, respectively. These results suggested that a larger amount of monomers and short oligomers of ADP-ribose was synthesized in adenomatous polyps, while a smaller number of longer polymers was produced in cancers as compared with normal mucosa. Immunohistochemical analysis of these tissues using anti-poly(ADP-ribose) antibody supported this view.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6406058

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Cell cycle perturbating agents in a line of human thyroid transformed cells in culture (HuT).

Authors:  A Mancini; M R Faraone-Mennella; P Quesada; M Malanga; B Farinai
Journal:  Mol Cell Biochem       Date:  1991-05-15       Impact factor: 3.396

2.  Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.

Authors:  Shailly Mehrotra; Mathangi Gopalakrishnan; Jogarao Gobburu; Jacqueline M Greer; Richard Piekarz; Judith E Karp; Keith Pratz; Michelle A Rudek
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

3.  Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.

Authors:  Ahmed Hamed Salem; Vincent L Giranda; Nael M Mostafa
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 4.  DNA repair dysregulation from cancer driver to therapeutic target.

Authors:  Nicola J Curtin
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

Review 5.  PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Authors:  Nilufer Jasmine Selimah Fauzee; Juan Pan; Ya-lan Wang
Journal:  Pathol Oncol Res       Date:  2010-04-12       Impact factor: 3.201

6.  Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.

Authors:  Minesh P Mehta; Ding Wang; Fen Wang; Lawrence Kleinberg; Anthony Brade; H Ian Robins; Aruna Turaka; Terri Leahy; Diane Medina; Hao Xiong; Nael M Mostafa; Martin Dunbar; Ming Zhu; Jane Qian; Kyle Holen; Vincent Giranda; Walter J Curran
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

Review 7.  Nicotinamide phosphoribosyltransferase in malignancy: a review.

Authors:  Rodney E Shackelford; Kim Mayhall; Nicole M Maxwell; Emad Kandil; Domenico Coppola
Journal:  Genes Cancer       Date:  2013-11

8.  Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Authors:  Reshma Jagsi; Kent A Griffith; Jennifer R Bellon; Wendy A Woodward; Janet K Horton; Alice Ho; Felix Y Feng; Corey Speers; Beth Overmoyer; Michael Sabel; Anne F Schott; Lori Pierce
Journal:  J Clin Oncol       Date:  2018-03-20       Impact factor: 44.544

9.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.

Authors:  T Zaremba; P Ketzer; M Cole; S Coulthard; E R Plummer; N J Curtin
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

10.  Induction of murine teratocarcinoma cell differentiation by suppression of poly(ADP-ribose) synthesis.

Authors:  Y Ohashi; K Ueda; O Hayaishi; K Ikai; O Niwa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.